Lifeboat Foundation

The CRISPR/Cas9 gene-editing tool is one of the most promising approaches to advancing treatments of genetic diseases—including cancer—an area of research where progress is constantly being made. Now, the Molecular Cytogenetics Unit led by Sandra Rodríguez-Perales at the Spanish National Cancer Research Centre (CNIO) has taken a step forward by effectively applying this technology to eliminate so-called fusion genes, which in the future could open the door to the development of cancer therapies that specifically destroy tumors without affecting healthy cells. The paper is published in Nature Communications.

Fusion genes are the abnormal result of an incorrect joining of DNA fragments that come from two different genes, an event that occurs by accident during the process of cell division. If the cell cannot benefit from this error, it will die and the fusion genes will be eliminated. But when the error results in a reproductive or survival advantage, the carrier cell will multiply and the fusion genes and the proteins they encode thus become an event triggering tumor formation. “Many chromosomal rearrangements and the fusion genes they produce are at the origin of childhood sarcomas and leukaemias,” explains Sandra Rodríguez-Perales, lead co-author of the study now published by the CNIO. Fusion genes are also found in among others prostate, breast, lung and brain tumors: in total, in up to 20% of all cancers.

Because they are only present in tumor cells, fusion genes attract a great deal of interest among the scientific community because they are highly specific therapeutic targets, and attacking them only affects the tumor and has no effect on healthy cells.

In the search for the chemical origins of life, researchers have found a possible alternative path for the emergence of the characteristic DNA pattern: According to the experiments, the characteristic DNA base pairs can form by dry heating, without water or other solvents. The team led by Ivan Halasz from the Rudjer Boskovic Institute and Ernest Mestrovic from the pharmaceutical company Xellia presents its observations from DESYs X-ray source PETRA III in the journal Chemical Communications.

“One of the most intriguing questions in the search for the origin of life is how the chemical selection occurred and how the first biomolecules formed,” says Tomislav Stolar from the Rudjer Boskovic Institute in Zagreb, the first author on the paper. While living cells control the production of biomolecules with their sophisticated machinery, the first molecular and supramolecular building blocks of life were likely created by pure chemistry and without enzyme catalysis. For their study, the scientists investigated the formation of nucleobase pairs that act as molecular recognition units in the Deoxyribonucleic Acid (DNA).

Our genetic code is stored in the DNA as a specific sequence spelled by the nucleobases adenine (A), cytosine ©, guanine (G) and thymine (T). The code is arranged in two long, complementary strands wound in a double-helix structure. In the strands, each nucleobase pairs with a complementary partner in the other strand: adenine with thymine and cytosine with guanine.

I will be 49 tomorrow. I always like to find some sort of life extension vid for my birthday. And boy did I hit it. Here comes Bill Faloon to drown you in info. Fruit flies 48% increase at 4:30, George Church at 9:00, C. Elegans 5X increase 15:30, 114 year old blood cells reprogrammed ti pluripotent at 18:40, epigenetics at 22:30, Senile plasma at 24:30, Dr Mike West 4 paragraphs to summarize at 21:00, 44:00 minutes is Vitality in Aging Interventions Trail which anyone can join. Enjoy.

California-based researchers develop a test that can detect the coronavirus using gene-editing technology and a modified mobile phone camera.

But people need to be kept at the centre of it.

There is more than one reason that we need to reforest Planet Earth. Less than a fifth of Earth’s original forests have survived the rise of humans since the last glaciation, and over half of them are in just five countries (see figure below).

The biggest effect from loss of forests is loss of habitat and the resultant loss of biodiversity, even if you don’t care about climate change. We’re burning billions of acres of pristine Indonesian rain forests to plant palm oil trees (Scientific American) just to get a cooking oil with a better shelf life.

Continue reading “Drones Can Reforest The Planet Faster Than Humans Can” »

Researchers have made a breakthrough genetic discovery into the cause of a spectrum of severe neurological conditions.

A research study, led by the Murdoch Children’s Research Institute (MCRI) and gracing the cover of and published in the October edition of Human Mutation, found two new mutations in the KIF1A gene cause rare nerve disorders.

MCRI researcher Dr. Simranpreet Kaur said mutations in the KIF1A gene caused ‘traffic jams’ in brain cells, called neurons, triggering a devastating range of progressive brain disorders. KIF1A-Associated Neurological Disorders (KAND) affects about 300 children worldwide.

Anxious couples are approaching fertility doctors in the US with requests for a hotly debated new genetic test being called “23andMe, but on embryos.”

The baby-picking test is being offered by a New Jersey startup company, Genomic Prediction, whose plans we first reported on two years ago.

The company says it can use DNA measurements to predict which embryos from an IVF procedure are least likely to end up with any of 11 different common diseases. In the next few weeks it’s set to release case studies on its first clients.

One of the most remarkable recent advances in biomedical research has been the development of highly targeted gene-editing methods such as CRISPR that can add, remove, or change a gene within a cell with great precision. The method is already being tested or used for the treatment of patients with sickle cell anemia and cancers such as multiple myeloma and liposarcoma, and today, its creators Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize in chemistry.

While gene editing is remarkably precise in finding and altering genes, there is still no way to target treatment to specific locations in the body. The treatments tested so far involve removing blood stem cells or immune system T cells from the body to modify them, and then infusing them back into a patient to repopulate the bloodstream or reconstitute an immune response—an expensive and time-consuming process.

Building on the accomplishments of Charpentier and Doudna, Tufts researchers have for the first time devised a way to directly deliver gene-editing packages efficiently across the blood brain barrier and into specific regions of the brain, into immune system cells, or to specific tissues and organs in mouse models. These applications could open up an entirely new line of strategy in the treatment of neurological conditions, as well as cancer, infectious disease, and autoimmune diseases.

Selection of just two scientists will stir controversy, given patent fight over genome editor’s discovery.